Neurocrine Biosciences
Work Here?
About
Company Stage
IPO
Employees
1,001-5,000
Industries
Biotechnology, Healthcare
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Simplify's Take
What believers are saying
- Positive Phase 2 data for NBI-1117568 in schizophrenia and the launch of INGREZZA SPRINKLE highlight Neurocrine's innovative pipeline and commitment to addressing unmet medical needs.
- The FDA's acceptance of crinecerfont's New Drug Applications with Priority Review could lead to a significant market breakthrough if approved.
- Recent investments and executive appointments suggest strong confidence in the company's future growth and strategic direction.
What critics are saying
- The pharmaceutical industry is highly competitive, and Neurocrine must continuously innovate to maintain its market position.
- Regulatory hurdles, such as FDA rejections, could delay product launches and impact financial performance.
What makes Neurocrine Biosciences unique
- Neurocrine Biosciences is pioneering in the treatment of congenital adrenal hyperplasia (CAH) with crinecerfont, a first-in-class therapy that hasn't seen innovation in 70 years.
- The company offers unique formulations like INGREZZA SPRINKLE, addressing specific patient needs such as dysphagia, which sets them apart in the pharmaceutical landscape.
- Their focus on rare and serious endocrine disorders, combined with successful clinical trials, positions them as a leader in niche therapeutic areas.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights
Headcount
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Neurocrine Biosciences is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
💡
We update Neurocrine Biosciences's jobs every 8 hours, so check again soon! Browse all jobs →